Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo
- PMID: 17289548
- DOI: 10.1016/j.autrev.2006.09.010
Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo
Abstract
Vitiligo is an acquired hypomelanotic disorder characterised by circumscribed depigmented macules in the skin resulting from the loss of functional melanocytes. Population surveys have shown a prevalence ranging from 0.38 to 1.13%. The frequent association of vitiligo with autoimmune diseases, together with studies demonstrating that vitiligo patients can have autoantibodies and autoreactive T lymphocytes against pigment cells supports the theory that there is an autoimmune involvement in the aetiology of the disease. Although the pathogenic mechanisms of T cells have recently been well studied in vitiligo, the role of autoantibodies in the disease remains obscure. However, even if antibodies to melanocytes are not an agent of the disease, identifying their target antigens could provide for the development of diagnostic tests that are not yet available for vitiligo and could serve as markers for important T cell responses in patients with the disease.
Similar articles
-
Autoimmunity as an aetiological factor in vitiligo.J Eur Acad Dermatol Venereol. 2007 Aug;21(7):865-76. doi: 10.1111/j.1468-3083.2007.02228.x. J Eur Acad Dermatol Venereol. 2007. PMID: 17658994 Review.
-
Apoptosis of melanocytes in vitiligo results from antibody penetration.J Autoimmun. 2007 Dec;29(4):281-6. doi: 10.1016/j.jaut.2007.07.012. Epub 2007 Sep 20. J Autoimmun. 2007. PMID: 17888626 Review.
-
Current remedies for vitiligo.Autoimmun Rev. 2010 May;9(7):516-20. doi: 10.1016/j.autrev.2010.02.013. Epub 2010 Feb 8. Autoimmun Rev. 2010. PMID: 20149899 Review.
-
The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.J Clin Invest. 2002 Apr;109(7):923-30. doi: 10.1172/JCI14643. J Clin Invest. 2002. PMID: 11927619 Free PMC article.
-
Immunopathogenesis of vitiligo.Autoimmun Rev. 2011 Oct;10(12):762-5. doi: 10.1016/j.autrev.2011.02.004. Epub 2011 Feb 18. Autoimmun Rev. 2011. PMID: 21334464 Review.
Cited by
-
Multiple gene-drug prediction tool reveals Rosiglitazone based treatment pathway for non-segmental vitiligo.Inflammation. 2024 Apr;47(2):678-695. doi: 10.1007/s10753-023-01937-9. Epub 2023 Dec 30. Inflammation. 2024. PMID: 38159176 Free PMC article.
-
Effect of Associated Autoimmune Diseases on Type 1 Diabetes Mellitus Incidence and Metabolic Control in Children and Adolescents.Biomed Res Int. 2016;2016:6219730. doi: 10.1155/2016/6219730. Epub 2016 Jul 20. Biomed Res Int. 2016. PMID: 27525273 Free PMC article. Review.
-
A Case of Vitiligo after Kawasaki's Disease.Ann Dermatol. 2009 Feb;21(1):75-7. doi: 10.5021/ad.2009.21.1.75. Epub 2009 Feb 28. Ann Dermatol. 2009. PMID: 20548863 Free PMC article.
-
Network pharmacological mechanisms of Vernonia anthelmintica (L.) in the treatment of vitiligo: Isorhamnetin induction of melanogenesis via up-regulation of melanin-biosynthetic genes.BMC Syst Biol. 2017 Nov 16;11(1):103. doi: 10.1186/s12918-017-0486-1. BMC Syst Biol. 2017. PMID: 29145845 Free PMC article.
-
Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease.Thyroid. 2010 Jul;20(7):745-54. doi: 10.1089/thy.2010.1643. Thyroid. 2010. PMID: 20578892 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical